RBC Capital Reiterates Outperform on PTC Therapeutics, Maintains $65 Price Target

Benzinga · 04/22 14:05
RBC Capital analyst Brian Abrahams reiterates PTC Therapeutics (NASDAQ:PTCT) with a Outperform and maintains $65 price target.